Harvard Bioscience Reports Third Quarter 2018 Financial Results October 25, 2018 -Reports GAAP andadjusted non-gaap revenue of $28.6 million and $28.7 million, respectively, an increase of 53% and15%, respectively- HOLLISTON, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company ), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and nine months ended September 30, 2018. Our financial performance this quarter was within our expectations and reflects our focus on growth, profitability and new product development, said Jeffrey Duchemin, President and CEO of Harvard Bioscience. With this quarter s improvements in reported and adjusted revenue, as well as improved adjusted gross profit, adjusted operating income, and adjusted net income, we remain on track to meet our full-year financial projections. Third Quarter Reported Results Revenue, as measured under generally accepted accounting principles, or GAAP, for the three months ended September 30, 2018 was $28.6 million, an increase of 53%, or $9.9 million, compared to revenue of $18.7 million for the three months ended September 30, 2017. Revenue, on a non-gaap basis, which includes revenue generated by Denville Scientific, Inc., or Denville, for the periods presented prior to its sale, and excludes purchase accounting adjustments, was $28.7 million for the three months ended September 30, 2018, an increase of approximately 15%, or $3.7 million, compared to revenue of $25.1 million for the three months ended September 30, 2017. For a reconciliation between GAAP and non-gaap revenue and changes in revenue, refer to Exhibit 4 below. Net loss, as measured under GAAP, was $0.3 million, or $0.01 per diluted share, for the three months ended September 30, 2018 compared to a net loss of $0.4 million, or $0.01 per diluted share, for the same quarter in 2017. The net loss for the three months ended September 30, 2017 was comprised of a $0.6 million loss from continuing operations and income of $0.2 million from discontinued operations. Net income, on a non-gaap basis, was $1.3 million, or $0.04 per diluted share, for the three months ended September 30, 2018, compared to $1.1 million, or $0.03 per diluted share, for the three months ended September 30, 2017. For a reconciliation between GAAP and non-gaap net income, and between GAAP and non-gaap diluted earnings per share, refer to Exhibits 7 and 8 below, respectively. Year-to-Date Reported Results Revenue, as measured under GAAP, for the nine months ended September 30, 2018 were $86.9 million, an increase of approximately 56%, or $31.2 million, compared to revenues of $55.8 million for the nine months ended September 30, 2017. Revenue, on a non-gaap basis, which includes revenue generated by Denville for the periods presented prior to its sale, and excludes purchase accounting adjustments, was $88.0 million for the nine months ended September 30, 2018, an increase of approximately 18%, or $13.6 million, compared to revenue of $74.4 million for the nine months ended September 30, 2017. For a reconciliation between GAAP and non-gaap revenue and changes in revenue, refer to Exhibit 4 below. Net loss, as measured under GAAP, was $5.8 million, or $0.16 per diluted share, for the nine months ended September 30, 2018 compared to $1.9 million, or $0.05 per diluted share, for the nine months ended September 30, 2017. The net loss for the nine months ended September 30, 2018 was comprised of a $7.6 million loss from continuing operations and income of $1.8 million from discontinued operations. The net loss for the nine months ended September 30, 2017 was comprised of a $2.0 million loss from continuing operations and income of $0.1 million from discontinued operations. Net income, on a non-gaap basis, was $4.6 million, or $0.13 per diluted share, for the nine months ended September 30, 2018 compared to $2.5 million, or $0.07 per diluted share, for the same period in 2017. For a reconciliation between GAAP and non-gaap net income, and between GAAP and non-gaap diluted earnings per share, refer to Exhibits 7 and 8 below, respectively. Financial Guidance As of today, the Company is amending its financial guidance for full year 2018 by tightening the expected ranges for both revenue and diluted earnings per share. The Company now expects 2018 revenue to be between $120 million and $121.5 million. This compares to the Company s prior guidance of between $120 million and $123 million, which was previously issued on May 2, 2018 and reaffirmed July 26, 2018. The Company now expects to report a full-year 2018 GAAP diluted loss per share of approximately $0.12 to $0.14 and non-gaap diluted earnings per share of approximately $0.20 to $0.22. This compares to the Company s prior guidance of full-year 2018 non-gaap diluted earnings per share of $0.20 to $0.23, which was previously issued on May 2, 2018 and reaffirmed on July 26, 2018. The Company may incur charges, realize gains, or experience other events in 2018 that could cause actual results to vary from this guidance. Refer to Exhibit 9 below for a reconciliation between the GAAP and non-gaap diluted earnings per share guidance. Webcast and Conference Call Details Harvard Bioscience will be hosting a conference call and webcast today at 4:30 pm ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer, and Corey Manchester, Corporate Controller, of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-888-771-4371, or international: 1-847-585-4405, and referencing the conference ID# 47737895. The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at http://investor.harvardbioscience.com/ and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website. If you are unable to listen to the live conference call, the webcast will be available on the Company's website through November 1, 2018. To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click remind me. Use of Non-GAAP Financial Information In this press release, we have included non-gaap financial information including adjusted revenue, adjusted gross profit, adjusted operating income, adjusted net income and adjusted earnings per diluted share. We believe that this non-gaap financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-gaap financial measures of revenue and income have excluded certain revenue and expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as currency translation, amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, gains or losses from divestitures, forensic investigation and remediation costs, severance and restructuring expenses, and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-gaap financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our non-gaap adjusted revenue, non-gaap adjusted gross profit, non-gaap adjusted operating income, non-gaap adjusted net income and non-gaap adjusted earnings per diluted share for the three and nine months ended September 30, 2018 and 2017 are included as exhibits below in this press release. The non-gaap financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP, and may be different than other companies non-gaap financial information. About Harvard Bioscience Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, the impact of acquisitions, or potential acquisitions, the outlook for the life sciences industry, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results to differ materially from those in the forward-looking statements include reductions in customers research budgets or government funding; the Company s failure to successfully integrate acquired businesses or technologies, including DSI; domestic and global economic conditions; economic, political and other risks associated with international revenues and operations; newly enacted U.S. government tax reform; currency exchange rate fluctuations; economic and political conditions generally and those affecting pharmaceutical and biotechnology industries; the seasonal nature of purchasing in Europe; the Company's failure to expand into foreign countries and international markets; the Company's inability to manage its growth; competition from the Company's competitors; failure or inadequacy of the Company's information technology structure; impact of difficulties implementing our enterprise resource planning systems; information security incidents or cybersecurity breaches; the Company's failure to identify potential acquisition candidates and successfully close such acquisitions with favorable; unanticipated costs relating to acquisitions and known and unknown costs arising in connection with the Company's consolidation of business functions and any restructuring initiatives; failure of any banking institution in which the Company deposits its funds or the institution's failure to provide services; the Company's substantial debt and its ability to meet the financial covenants contained in its credit facility; the Company's failure to raise or generate capital necessary to implement its acquisition and expansion strategy, expand operation and invest in new products; the failure of Biostage, Inc., f/k/a Harvard Apparatus Regenerative Technology, Inc., or Biostage, to indemnify the Company for any liabilities associated with Biostage s business; impact of any impairment of the Company's goodwill or intangible assets; the Company's ability to retain key personnel; rising commodity and precious metals costs; the Company's ability to protect its intellectual property and operate without infringing on others' intellectual property; exposure to product and other liability claims; plus factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2017 or otherwise described in our other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. For investor inquiries, please call (508) 893-8066. Press releases may be found on the Harvard Bioscience website. Exhibit 1
Condensed Consolidated Balance Sheet Information Assets September 30, December 31, 2018 2017 Cash and cash equivalents $ 6,661 $ 5,192 Trade receivables 17,880 13,382 Inventories 25,739 16,848 Property, plant and equipment 5,392 3,743 Goodwill and other intangibles 103,149 47,610 Other assets 6,219 4,215 Assets held for sale - 18,364 Total assets $ 165,040 $ 109,354 Liabilities and Stockholders' Equity Total liabilities $ 84,081 $ 28,454 Stockholders equity 80,959 80,900 Total liabilities and stockholders equity $ 165,040 $ 109,354 Exhibit 2 Consolidated Statements of Operations (In thousands, except per share data) (unaudited) Revenues $ 28,635 $ 18,717 $ 86,916 $ 55,761 Cost of revenues 12,818 9,217 42,475 27,611 Gross profit 15,817 9,500 44,441 28,150 Sales and marketing expenses 6,021 3,635 17,976 10,663 General and administrative expenses 4,655 4,317 15,297 13,219 Research and development expenses 2,783 1,538 7,943 4,119 Amortization of intangible assets 1,468 400 3,983 1,158 Total operating expenses 14,927 9,890 45,199 29,159 Operating income (loss) 890 (390 ) (758 ) (1,009 ) Other expense: Foreign exchange (26 ) (73 ) (28 ) (488 ) Interest expense, net (1,458 ) (189 ) (3,835 ) (532 ) Other expense, net (314 ) (12 ) (3,399 ) (117 ) Other expense, net (1,798 ) (274 ) (7,262 ) (1,137 ) Loss from continuing operations before income taxes (908 ) (664 ) (8,020 ) (2,146 ) Income tax benefit (652 ) (19 ) (416 ) (141 ) Loss from continuing operations (256 ) (645 ) (7,604 ) (2,005 ) Discontinued operations Income from discontinued operations - 254 937 231 Income tax expense (benefit) - 26 (883 ) 90 (Loss) income from discontinued operations, net of tax - 228 1,820 141 Net loss $ (256 ) $ (417 ) $ (5,784 ) $ (1,864 )
Loss per share: Basic loss per common share from continuing operations $ (0.01 ) $ (0.02 ) $ (0.21 ) $ (0.06 ) Discontinued operations - 0.01 0.05 - Basic loss per common share $ (0.01 ) $ (0.01 ) $ (0.16 ) $ (0.05 ) Diluted loss per common share from continuing operations $ (0.01 ) $ (0.02 ) $ (0.21 ) $ (0.06 ) Discontinued operations - 0.01 0.05 - Diluted loss per common share $ (0.01 ) $ (0.01 ) $ (0.16 ) $ (0.05 ) Weighted average common shares: Basic 36,947 34,840 36,170 34,706 Diluted 36,947 34,840 36,170 34,706 Exhibit 3 Condensed Consolidated Cash Flow Information Nine Months Ended September 30, 2018 2017 Cash flows from operations: Net loss $ (5,784 ) $ (1,864 ) Changes in assets and liabilities (1,090 ) (1,646 ) Other adjustments to operating cash flows 7,085 5,506 Net cash provided by operating activities 211 1,996 Investing activities: Additions to property, plant and equipment (891 ) (677 ) Acquisitions, net of cash acquired (68,007 ) - Dispositions, net of cash sold 15,755 - Other investing activities (24 ) (39 ) Net cash used in investing activities (53,167 ) (716 ) Financing activities: Proceeds from issuance of debt 70,800 2,250 Repayments of debt (19,947 ) (3,502 ) Other financing activities 2,632 (101 ) Net cash provided by (used in) financing activities 53,485 (1,353 ) Effect of exchange rate changes on cash 399 313 Increase in cash and cash equivalents 928 240 Cash and cash equivalents at the beginning of period, including cash included in assets held for sale 5,733 5,596 Cash and cash equivalents at the end of period $ 6,661 $ 5,836 Exhibit 4 Reconciliation of GAAP Revenue to Non-GAAP Adjusted Revenue 2018 2017 Change (%) 2018 2017 Change (%) GAAP revenue $ 28,635 $ 18,717 53 % $ 86,916 $ 55,761 56 %
Denville revenue reported within discontinued operations - 6,333-100 % 893 18,658-95 % Deferred revenue valuation adjustments on acquisition 78-100 % 207-100 % Non-GAAP adjusted revenue $ 28,713 $ 25,050 15 % $ 88,016 $ 74,419 18 % Foreign exchange effect on Non-GAAP adjusted revenue -1 % 3 % Exhibit 5 Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Profit GAAP gross profit $ 15,817 $ 9,500 $ 44,441 $ 28,150 Denville Non-GAAP adjusted gross profit - 2,140 360 6,279 Deferred revenue valuation charges on acquisition 78-207 - Inventory valuation step-up charges on acquisition 87-3,816 - Severance and restructuring charges 22 14 42 92 Stock-based compensation expense 19 16 45 44 Non-GAAP adjusted gross profit $ 16,023 $ 11,670 $ 48,911 $ 34,565 GAAP gross profit percentage 55.2 % 50.8 % 51.1 % 50.5 % Non-GAAP adjusted gross profit percentage 55.8 % 46.6 % 55.6 % 46.4 % Exhibit 6 Reconciliation of GAAP Operating Income (Loss) to Non-GAAP Adjusted Operating Income GAAP operating income (loss) $ 890 $ (390 ) $ (758 ) $ (1,009 ) Amortization of intangible assets 1,468 400 3,983 1,158 Denville Non-GAAP adjusted operating income - 503 17 1,033 Deferred revenue valuation charges on acquisition 78-207 - Inventory valuation step-up charges on acquisition 87-3,816 -
Forensic investigation and remediation costs - - - 386 Severance and restructuring charges 198 127 645 328 Stock-based compensation expense 486 908 2,082 2,530 Non-GAAP adjusted operating income $ 3,207 $ 1,548 $ 9,992 $ 4,426 Exhibit 7 Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Income GAAP net loss $ (256 ) $ (417 ) $ (5,784 ) $ (1,864 ) Amortization of intangible assets 1,468 400 3,983 1,158 Denville Non-GAAP adjustments included in discontinued operations (A) - 249 (920 ) 798 Deferred revenue valuation charges on acquisition 78-207 - Inventory valuation step-up charges on acquisition 87-3,816 - Forensic investigation and remediation costs - - - 386 Severance and restructuring charges 198 127 645 328 Acquisition, disposition and integration costs 202 6 3,047 80 Stock-based compensation expense 486 908 2,082 2,530 Income taxes (B) (947 ) (212 ) (2,481 ) (867 ) Non-GAAP adjusted net income $ 1,316 $ 1,061 $ 4,595 $ 2,549 (A) For the three months ended September 30, 2017, the non-gaap adjustments reported in discontinued operations related to the sale of Denville included $222 in amortization of intangible assets, $2 in severance and restructuring charges, and $25 in stock-based compensation expense. For the nine months ended September 30, 2018, the non-gaap adjustments reported in discontinued operations related to the sale of Denville included a $1,251 gain on sale, $47 in amortization of intangible assets, $132 in disposition costs, and $150 in stock-based compensation expense. For the nine months ended September 30, 2017, the non-gaap adjustments reported in discontinued operations related to the sale of Denville included $667 in amortization of intangible assets, $57 in severance and restructuring charges, and $74 in stock-based compensation expense. (B) Income taxes includes the tax effect of adjusting for the reconciling items using the calculated effective tax rate, including the post-2017 impact of tax reform, in the jurisdictions in which the reconciling items arise. Exhibit 8 Reconciliation of GAAP Diluted Loss Per Common Share to Non-GAAP Adjusted Diluted Earnings Per Common Share (unaudited)
GAAP diluted loss per common share $ (0.01 ) $ (0.01 ) $ (0.16 ) $(0.05 ) Amortization of intangible assets 0.04 0.01 0.11 0.03 Denville Non-GAAP adjustments included in discontinued operations - 0.01 (0.03 ) 0.02 Deferred revenue valuation charges on acquisition - - 0.01 - Inventory valuation step-up charges on acquisition - - 0.11 - Forensic investigation and remediation costs - - - 0.01 Severance and restructuring charges 0.01-0.02 0.01 Acquisition, disposition and integration costs 0.01-0.08 - Stock-based compensation expense 0.01 0.03 0.06 0.07 Income taxes (A) (0.02 ) (0.01 ) (0.07 ) (0.02 ) Non-GAAP adjusted diluted earnings per common share $ 0.04 $ 0.03 $ 0.13 $0.07 (A) Income taxes includes the tax effect of adjusting for the reconciling items using the calculated effective tax rate for the consolidated entity and any changes to valuation allowances. Exhibit 9 Reconciliation of Guidance for 2018 GAAP Diluted Loss per Common Share to Non-GAAP Adjusted Diluted Earnings per Common Share (unaudited) GAAP diluted loss per common share (A) $ (0.12) - (0.14) Amortization of intangible assets 0.16 Denville Non-GAAP adjustments included in discontinued operations (0.03 ) Deferred revenue valuation charges on acquisition 0.01 Inventory valuation step-up charges on acquisition 0.11 Severance and restructuring charges 0.02 Acquisition, disposition and integration costs 0.08 Stock-based compensation expense 0.08 Income taxes (B) (0.09 ) Non-GAAP adjusted diluted earnings per common share (A) $ 0.20-0.22 (A) This guidance excludes, among other things, the impact of future acquisitions, acquisition costs, restructuring charges, or other one time charges.
(B) Income taxes includes the tax effect of adjusting for the reconciling items using the calculated effective tax rate, including the post-2017 impact of tax reform, in the jurisdictions in which the reconciling items arise and any changes to valuation allowances. CONTACTS: Corey Manchester Corporate Controller Tel: 508 893 8999 Source: Harvard Bioscience, Inc.